Trump signs order raising Canada tariffs to 35% from 25%
SAN DIEGO - Gossamer Bio, Inc. (NASDAQ:GOSS), a biopharmaceutical company in the clinical stage with a market capitalization of $225 million, has shared new research findings on its drug candidate seralutinib, at the recent Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress in Rio de Janeiro, Brazil. The company’s stock has shown strong momentum, gaining nearly 9% in the past week. According to InvestingPro analysis, the company maintains a healthy financial position with liquid assets exceeding short-term obligations. The event, which took place from January 29th to February 1st, featured an oral presentation and three posters detailing the potential benefits of seralutinib in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The presented studies included preclinical models indicating that seralutinib may work synergistically with another drug, sotatercept, in treating PAH. Additionally, a post-hoc analysis of the TORREY open-label extension study suggested sustained benefits of seralutinib treatment. Another poster reported a sustained effect of the drug on circulating biomarkers in the TORREY Phase 2 open-label extension study. With a strong current ratio of 6.74, InvestingPro data suggests the company is well-positioned to continue its research programs. Five analysts have recently revised their earnings expectations upward, reflecting growing confidence in the company’s pipeline.
Gossamer Bio aims to become a leader in the treatment of pulmonary hypertension and improve the lives of patients affected by this condition. Seralutinib, an inhaled PDGFR, CSF1R, and c-KIT inhibitor, is central to the company’s development efforts in this therapeutic area. While the company is currently operating at a loss, InvestingPro analysis indicates the stock is trading below its Fair Value, potentially presenting an opportunity for investors interested in clinical-stage biotech companies.
The information presented at the PVRI Congress is based on a press release statement from Gossamer Bio. The company continues to investigate the efficacy and safety of seralutinib, with the goal of addressing the unmet medical needs of patients with pulmonary hypertension. As with all clinical research, these findings will undergo further scrutiny and validation within the scientific community.
In other recent news, investment bank Piper Sandler has released a detailed update on potential catalysts for biotechnology companies up to 2025, following a comprehensive review of third-quarter 2024 earnings and year-end 2024 data. The firm has identified approximately 190 direct and over 150 indirect catalysts that may impact the firms they cover. These catalysts include competitive mechanisms of action and indications that could serve as turning points for investors.
Companies such as Immunovant (NASDAQ:IMVT), Praxis Precision Medicines, and Prothena Corporation are anticipated to have the most direct catalysts within the next 12 months. Each of these companies is expected to present at least three significant data catalysts. In terms of indirect catalysts, GPCR Therapeutics and NAMS are highlighted in the report for their potential positive influence.
The report also covers the potential for relaxin-related treatments that could boost confidence in TECX’s TX45, a RXFP1 agonist, ahead of its Phase 1b readout. Piper Sandler has identified six stocks with de-risked Phase 3 readouts or interim analyses expected in 2025, including aTYR Pharma, Cytokinetics (NASDAQ:CYTK), GOSS, Immunovant, Praxis Precision Medicines, and Prothena Corporation. Lastly, several companies with key Phase 2b readouts expected in 2025 were outlined, such as Altimmune (NASDAQ:ALT), AnaptysBio (NASDAQ:ANAB), Edgewise Therapeutics, GPCR Therapeutics, Immunic (NASDAQ:IMUX), Lexicon Pharmaceuticals (NASDAQ:LXRX), Nektar Therapeutics (NASDAQ:NKTR), Praxis Precision Medicines, Prothena Corporation, Termolex, and Unity Biotechnology (NASDAQ:UBX).
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.